Figure 5

Combination of circulating tumor cell (CTC) status at any time point and known clinicopathologic risk factors, extracapsular extension (ECE) and/or margin status, can predict for time to biochemical failure following adjuvant or salvage radiotherapy. (a) Percentage of patients who are biochemical failure free over a 36-month period and who presented with ECE, but without CTCs (CTC^neg/-; n=29), at all time points versus patients with ECE, but with CTCs (CTC^pos/+; n=9), at any time point (P=0.025). (b) Percentage of patients who are biochemical failure free over a 36-month period and who presented with positive margins (margins), but CTC^neg (n=25), at all time points versus patients with positive margins, but CTC^pos (n=6), at any time point (P=0.001). (c) Percentage of patients who are biochemical failure free over a 36-month period and who presented with seminal vesicle invasion (SVI), but CTC^neg (n=4), at all time points versus patients with SVI, but CTC^pos (n=4), at any time point (P=0.128). (d) The percentage of patients who are biochemical failure free over a 36-month period and who presented with positive margins and ECE, but CTC^neg (n=15), at all time points versus patients with positive margins and ECE, but CTC^pos (n=2), at any time point (P<0.0001).